Table 3.

Change in lipoprotein(a) stratified by baseline lipoprotein(a) level at 1-month follow-up in propensity-score matching analysis.

	All Matched Population			Lipoprotein(a) <20 mg/dL
	Evolocumab + Statin	Statin	P value	Evolocumab + Statin	Statin	P value
Number of patients	131	131		44	59
Baseline, mg/dL	26.1 (17.5, 50.4)	24.7 (13.1, 45.2)	0.141	15.0 (10.4, 17.5)	12.7 (10.2, 15.9)	0.16
1-month, mg/dL	20.8 (9.4, 50.6)	30.7 (14.2, 63.5)	0.025	7.4 (3.9, 12.2)	13.6 (8.3, 19.7)	<0.001
Absolute change, mg/dL	−4.7 (−9.9, 1.4)	5.4 (−0.1, 14.7)	<0.001	−4.9 (−8.5, −1.3)	0.9 (−1.7, 5.5)	<0.001
Percent change, %	−18.6 (−46.0, 5.8)	20.8 (−1.1, 52.2)	<0.001	−39.3 (−60.7, −19.6)	9.9 (−16.0, 50.0)	<0.001
	20≤ Lipoprotein(a) <50 mg/dL			Lipoprotein(a) ≥50 mg/dL
	Evolocumab + Statin	Statin	P value	Evolocumab + Statin	Statin	P value
Number of patients	52	41		35	31
Baseline, mg/dL	30.7 (23.8, 37.3)	31.0 (25.6, 39.2)	0.462	70.7 (56.5, 93.3)	79.3 (61.6, 110.5)	0.169
1-month, mg/dL	21.9 (15.4, 41.1)	42.2 (32.2, 55.8)	<0.001	75.8 (50.6, 112.8)	109.0 (63.5, 128.6)	0.014
Absolute change, mg/dL	−5.0 (−13.9, 1.9)	10.7 (4.6, 21.9)	<0.001	−0.2 (−9.9, 16.9)	12.2 (2.9, 35.6)	0.005
Percent change, %	−18.6 (−44.5, 7.5)	41.9 (13.3, 63.7)	<0.001	−0.2 (−16.0, 17.6)	20.0 (3.8, 47.4)	0.004

Data are shown as median (Q1, Q3). The matching was based on age, sex, and baseline lipoprotein(a) level.